Spatial Genomics and Transcriptomics Market

Spatial Genomics and Transcriptomics Market by Type of Solution, Type of Sample, End Users, Research Areas and Key Geographical Regions: Industry Trends and Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    195

  • Pages
    321

  • View Count
    13862

Spatial Genomics and Transcriptomics Market Overview

The spatial genomics and transcriptomics market is estimated to be worth $4.7 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 11.9% during the forecast period. Since the discovery of the first human genetic map in 1987, the field of omics-based analysis has evolved significantly. Researchers have focused their efforts from decoding the primary sequence of genes to analyzing the location and interaction of cell types, and biomarkers (primarily, DNA, RNA and proteins), through a process known as spatial phenotyping.

The traditional molecular profiling analytical techniques, such as microarrays quantitative polymerase chain reaction (qPCR), flow cytometry, mass spectrometry, immunohistochemistry and enzyme linked immunosorbent (ELISA) assay, though widely adopted, are known to dissociate the tissue samples, thereby causing loss of critical spatial multi-omics information across the genome, transcriptome, and proteome. This unmet need in the life sciences research market has prompted innovators to amalgamate cell imaging and molecular profiling techniques to enable visualization, as well as high-throughput quantification of the cells and biomarkers within the tissue samples.

The solutions (that include platforms, along with affiliated reagents and software applications) enable the researchers to further advance and scale their research, by offering a better understanding of the disease morphology, discover novel biomarkers and develop precision therapies. Additionally, these spatial phenotyping platforms can be seamlessly integrated with the current NGS-workflows. Therefore, the adoption of these novel devices to scale research from discovery to translational and clinical phases, is on the rise. In fact, according to a recent survey, approximately 44% of respondents expressed their intent to purchase a spatial profiling platform. In the same year, a research study, published in JAMA Oncology, emphasized the superiority of spatial phenotyping methods for the biomarker analysis in patients suffering from immuno-oncological diseases. Further, Nature Methods dubbed Spatial Transcriptomics as “Method of the Year” for 2020.

In order to capitalize the growing opportunity within this niche market, the developers of  spatial genomics and transcriptomics solutions are engaged in efforts to improve the penetration of their proprietary technologies, within the diverse client base, including academic research centers, research institutes and biopharma companies. As a result, they are engaged in incorporating advanced features to their devices, including machine learning-based image analysis, automated sample processing, high-multiplexing, and biomarker-specific gene panels (including those associated with SARS-CoV-2). At the same time, the cost of running these complex tests has dramatically decreased in recent years; the spatial analysis of high-plex stained panels now costs USD 1,000 per slide, which is similar to the cost of whole genome sequencing by next generation sequencing. Further, these instruments are designed to be capable of processing formalin-fixed paraffin embedded (FFPE) tissue sample. This feature is important because nearly 80% of the translational research studies, that use tissue samples, are dependent on the aforementioned sample type. Few players have also introduced customized access programs for biopharmaceutical players, enabling them to leverage spatial omics technologies, for the purpose of guiding their drug development programs. Driven by the growing adoption and continuous innovation of spatial biology solutions, we are led to believe that the opportunity for spatial profiling solution providers is likely to witness a sustained market growth over the forecast period.

This image provides list of Spatial Profiling Solutions. Over 60 solutions are available / being developed to visualize the spatial distribution of DNA, RNA and protein biomarkers in the tissue specimens; ~30% of these are accessible via the Product-as-a-Service business model This image presents current market landscape of Spatial Profiling Solutions. These instruments are integrated with several features to enable high-plex spatial phenotyping of biomarker signatures in tissue samples of human and / or murine origin, primarily to accelerate cancer-related research This image highlights the geographical distribution of Spatial Profiling Solutions Developers. Close to 95% of the spatial molecular profiling solution developers are based in North America and Europe; within North America, majority of the players are based in the US, specifically California and Massachusetts

Spatial Genomics and Transcriptomics Market Segments Updates

Market Share by Type of Solution 

The overall spatial genomics and transcriptomics market is segmented into instruments, consumables and services. Our estimates suggest that the due to the relatively higher price of instruments, the market is likely to be driven by the revenues generated through the sales of spatial-omics instruments and this trend is unlikely to change in the foreseen future. Further, the expanding instrument base is likely to drive recurring reagents and software revenue stream; as a result, the share of consumables and software segment is expected to grow at a relatively faster pace.

Market Share by Type of Sample 

This section distributes the overall spatial genomics and transcriptomics market revenues across the sample type analyzed, which includes proteins, RNA and DNA. In January 2024, Akoya Biosciences and Thermo Fisher Scientific announced a licensing and distribution agreement allowing Akoya to market the combination of its spatial biology solutions with the Thermo Fisher ViewRNA In Situ Hybridization Assays, for detection of protein and RNA biomarkers in tissue samples.

Market Share by End Users 

This section segments the spatial genomics and transcriptomics market on the basis of the end users that are employing various spatial omics solutions; these include pharmaceutical and biotechnology companies, and academic and research institutes. The maximum revenue share (90%) of the current market is generated through the sales of spatial omics solutions to pharmaceutical and biotechnology companies. This can be attributed to the fact that big pharma is evaluating several spatial omics platforms that can be seamlessly integrated into their process workflows for more accurate biomarker identification to advance their preclinical and clinical drug candidates.

Market Share by Research Areas

The overall spatial genomics and transcriptomics market is segmented on the basis of research areas targeted by the spatial solutions; these pertain to various therapeutic areas, namely into oncological / immuno-oncological disorders, immunological disorders, neurological disorders, infectious diseases and others. Presently, owing to the heightened focus and significant investment dedicated to the discovery of predictive biomarkers in oncology and immuno-oncology, the maximum revenue generation potential is associated with projects intended for the spatial detection of tumor microenvironment and this trend is unlikely to change in future. 

Market Share by Geographical Regions

This segment highlights the distribution of spatial genomics and transcriptomics market across various geographies, namely North America, Europe, Asia-Pacific and Rest of the World. According to our projections, North America currently captures nearly half of the overall market share. Further, owing to the increasing patient recruitment for biomarker-based clinical trials and growing number of contract manufacturing companies for medical devices in the Asia-Pacific region, the market is likely to grow at a relatively faster pace, during the given time period.

Spatial Genomics and Transcriptomics Market: Key Insights

Market Size Analysis:  Growing Adoption of Spatial Omics Solutions to Drive the Market Growth

The spatial genomics and transcriptomics market is anticipated to grow at CAGR of 11.9% during the forecast period. The market size is estimated to reach $ 21.1 billion by 2035. The rise will primarily be driven by the paradigm shift from broad-spectrum interventions to biomarker-targeted drugs and diagnostics. Further, the expanding applications of spatial omics solutions, from research domains like cancer, neuroscience, and immunology to translational and clinical phases, is expected to fuel further growth. Additionally, the increasing adoption of integrated omics technologies, including genomics and proteomics, is anticipated to play a pivotal role in driving market expansion.

Market Trends: Strategic Partnerships and Intellectual Property Surge in the Spatial Omics Market

The spatial genomics and transcriptomics market has seen an increase in partnership activity, growing at a CAGR of over 70%. This trend underscores the growing interest among solution providers to diversify their product portfolios and enhance the capabilities of existing instruments. Notably, integration agreements for spatial omics solutions with contemporary staining assays/reagents constitute a significant portion, accounting for 18% of total deals since 2016. In January 2024, AtlasXomics and EpiCypher partnered to develop CUT&Tag kits and assay services for spatial epigenomics applications. In February 2024, DNAnexus and Curio Bioscience teamed up to streamline data analysis for large-scale spatial transcriptomics projects, enabling customers of Curio Seeker Spatial Mapping Kit to utilize DNAnexus Precision Health Data Cloud for processing unbiased datasets across various tissue types and species.

Moreover, the landscape is marked by a substantial intellectual property presence, with over 500 patents/patent applications globally, highlighting the intense research and development efforts ongoing in the market.

Regional Trends: North America to Hold the Largest Share in the Spatial Genomics and Transcriptomics Market

Over 72% of the companies offering spatial genomics and transcriptomics solutions are headquartered in North America, followed by companies based in Europe. Further, close to 50% of the global market for spatial omics solutions is anticipated to be captured by companies based in North America; this trend is likely to remain the same in future as well. In March 2024, Lunaphore (the swiss subsidiary of Bio-Techne), partnered with Nikon Instruments to expand access to spatial biology contract services in the US by deploying Lunaphore's Comet spatial instrument at Nikon's BioImaging Lab in Boston.

Key Companies in Spatial Genomics and Spatial Transcriptomics Market

Examples of key companies engaged in spatial genomics and transcriptomics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include 10x Genomics, Akoya Biosciences, Bruker, Canopy Biosciences, Lunaphore Technologies, Molecular Machines & Industries (MMI), Resolve Biosciences, NanoString Technologies and Vizgen. This market report includes an easily searchable excel database of all the companies providing spatial genomics and transcriptomics solutions, worldwide.

Recent Developments in Spatial Genomics and Transcriptomics Market:

Several recent developments have taken place in the field of spatial genomics and transcriptomics. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, Acrobat Genomics, NanoString Technologies and Illumina Accelerator entered into a collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics by utilizing GeoMx® Digital Spatial Profiling (DSP) technology. Additionally, the collaboration aims to improve the treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis. 
  • In May 2023, 10x Genomics launched a new Visium CytAssist Gene and Protein Expression product with an aim to strengthen its Visium CytAssist spatial analysis capabilities. 
  • In March 2024, 10x Genomics commercially launched Visium HD Spatial Gene Expression Assay, empowering researchers to analyze the entire transcriptome from FFPE tissues at single cell resolution.
  • In March 2024, the University of California, San Diego researchers published a study in Nature unveiling a single-cell transcriptomics and spatially informed heart atlas, offering insights into heart development, function, and disease.
  • In February 2023, Vizgen presented new capabilities and data from the MERSCOPE™ spatial transcriptomics platform at Advances in Genome Biology and Technology (AGBT) general meeting.
This image highlights competitive analysis of Spatial Analysis Solutions. In pursuit of building a competitive edge, stakeholders are actively incorporating advanced features in their respective portfolio of devices to enable fast, high-plex and reproducible spatial analysis of tissue samples This image highlights the partnership activity undertaken by players engaged in Spatial Genomics Transcriptomics and Proteomics Solutions Market. With the growing interest in the field of spatial profiling and analysis of tissues, several partnerships have been established between solution providers and other stakeholders engaged in this domain This image presents review of close to 1,135 peer-reviewed, scientific articles related to spatial omics solutions. In the last two decades, several articles discussing various spatial molecular analysis techniques have been published in various scientific journals, thereby indicating the rapid pace of research activity, within this domain

Scope of the Report

The “Spatial Genomics and Transcriptomics Market by Type of Solution (Instruments, Consumables and Services), Type of Sample (DNA, RNA and Proteins), End Users (Pharmaceutical and Biotechnology Companies, and Academic and Research institutes), Research Areas (Oncology, Immunology, Neurology, Infectious and Others), and Key Geographical Regions (North America, Europe, and Asia-Pacific and the Rest of the World): Industry Trends and Forecasts, 2022-2035” market report offers an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the spatial genomics and transcriptomics market. The market research report underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in spatial genomics and transcriptomics. Amongst other elements, the market report includes:

  • A detailed assessment of the current market landscape of the spatial genomics and transcriptomics, highlighting the contributions of industry players, along with information on their year of establishment, company size, company ownership, location of headquarters, commercial availability, type of solution(s) offered, type of sample(s) analyzed (fresh frozen, FFPE, tissue microarrays and cellular), compatible sample source (human and murine), supported labware for sampling (test tubes, slides and well plates), type of molecule(s) analyzed (RNA, DNA and protein), detection method(s) used (fluorescence, brightfield and mass spectrometry), maximum plex level, quantification capability of analyte, research area(s) and  application area(s).
  • A detailed competitiveness analysis of products (devices / platforms / assays) based on parameters, such as supplier power (based on the experience of the developer and company size) and product specifications (type of sample analyzed, supported labware for sampling, type of molecule analyzed, detection method used, maximum plex level, quantification capability and compatible sample source).
  • Elaborate profiles of key players offering spatial omics solutions. Each profile includes a brief overview of the company, its financial information (if available), information on its spatial biology solutions portfolio, recent developments, and an informed outlook.
  • An analysis of the partnerships that have been established in spatial genomics and transcriptomics during 2017-2022, featuring a detailed set of analyses based on various parameters, such as type of partnership, year of partnership, therapeutic areas involved, geographical location of the companies involved and the most active players.
  • An in-depth analysis of the patents that have been filed / granted for spatial omics solutions since 2003, based on important parameters such as, type of patent, patent application year, publication year, granted patents, year-wise trend of filed patent applications, number of granted patents and patent applications, geography, patent age, type of applicant, CPC symbols, leading industry and non-industry players (on the basis of number of patents), and individual patent assignees (in terms of size of intellectual property portfolio). The chapter also includes an insightful benchmarking and valuation analysis. 
  • A detailed review of more than 600 peer-reviewed, scientific articles related to research on spatial omics solutions, based on parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on the top journals, top publishers and top copyright holders (in terms of number of articles published)
  • A detailed review of the overall landscape of the live cell instruments market, highlighting the contributions of industry players, along with information on their year of establishment, company size, geographical location of headquarters, ownership, commercial availability, microscope configuration, instrument weight, availability of integrated incubator, environmental parameters controlled, availability of multi-user mode, supported labware, Z-stack imaging capability, autofocusing capability, mode of imaging, number of fluorescent channels and magnification.
  • A detailed overview of genome sequencing technologies landscape, featuring information on type of applications, run time, maximum reads per run, maximum sequencing output, maximum read length, type of sequencing technique, quality score and cost. It also provides information on the technology providers involved in spatial genomics and spatial transcriptomics, including information on year of establishment, company size and geographical location.
This image provides information on patents that have been filed / granted related to spatial omics solutions. Over 500 patents / patent applications related to technologies, reagents and methods for spatial profiling, have been granted / filed across different jurisdictions, globally, by both industry and non-industry players This image provides information on the current and future market trends and potential growth of Spatial Profiling Solutions Market. Driven by the increasing adoption of spatial-omics solutions over contemporary technologies for biomarker analysis, the spatial profiling solutions market is expected to grow at a CAGR of ~15%, between 2022-2035 This image highlights the market segments of Spatial Profiling Solutions Market. The projected market opportunity is likely to be well distributed across different types of solutions, sample types, research areas, end users and key geographical regions

The key objective of spatial genomics and transcriptomics market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for spatial genomics and transcriptomics market during the forecast period. We have developed informed estimates on the evolution of the market for the forecast period 2022-2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across different segments; type of solution (instruments, services, consumables and software), type of sample analyzed (DNA, RNA and proteins), end user (academic research institutes and pharmaceutical companies), research areas (oncology, immunology, neurology, infectious and others), and key geographical locations (North America, Europe and Asia- Pacific and the Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, which represent different tracks of the industry’s growth. 

The opinions and insights presented in the market research report were influenced by discussions held with several stakeholders engaged in spatial genomics and transcriptomics. The market report features detailed transcripts of discussions held with the following individuals:

  • Senior Director, Mid-sized Company, US
  • Co-founder, Small Company, US
  • Senior Vice President of Marketing, Small Company, US

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is spatial genomics?

Answer: Spatial genomics refers to the study of genome expression within cells in their native tissue environment.

Question 2: How big is the spatial genomics and transcriptomics market?

Answer: The spatial genomics and transcriptomics market size is estimated to be worth $4.7 billion in 2022.

Question 3: What is the projected market growth of the spatial genomics and transcriptomics market?

Answer: The spatial genomics and transcriptomics market is expected to grow at compounded annual growth rate (CAGR) of 11.9% during the forecast period 2022 - 2035.

Question 4: Who are the leading players in the spatial genomics and transcriptomics market?

Answer: Examples of key companies engaged in spatial genomics and transcriptomics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include 10x Genomics, Akoya Biosciences, Bruker, Canopy Biosciences, Lunaphore Technologies, Molecular Machines & Industries (MMI), Resolve Biosciences, NanoString Technologies and Vizgen.

Question 5: How many solutions are presently being offered by the companies engaged in the spatial genomics and transcriptomics market?

Answer: Presently, over 70 solutions for the spatial analysis and profiling of tissue habitat are being offered by the companies engaged in the spatial genomics and transcriptomics market, globally.

Question 6: Which region is the hub for companies providing spatial genomics and transcriptomics solutions?

Answer: North America and Europe emerged to be the hub for companies providing spatial genomics and transcriptomics solutions, with over 90% of the companies based in these regions.

Question 7: How many patents are filed / granted related to spatial genomics and transcriptomics solutions?

Answer: Till date, over 500 patents have been filed / granted related to spatial genomics and transcriptomics solutions.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com